Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
FBR Capital Starts Keryx Biopharmaceuticals (KERX) at Market Perform
August 10, 2015 5:46 PM EDTFBR Capital initiates coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Market Perform rating and a price target of $10.00.
Analyst Christopher S. James commented, "Keryx is a commercial-stage company that markets Auryxia (ferric citrate) for the treatment of hyperphosphatemiaabnormally high phosphate levels in the bloodin chronic kidney disease... More
BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
August 6, 2015 10:01 AM EDTBTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
